文献速递临床微生物质量管理与危急值

氨曲南-阿维巴坦梯度扩散药敏试验的多中心性能评估

A multicenter performance evaluation of aztreonam-avibactam gradient diffusion susceptibility testing for Enterobacterales.
PubMed 文献 · J Clin Microbiol · 2026-04-20

该研究在四个中心评估ETEST AZA梯度扩散法对比参考肉汤微量稀释法,检测650株肠杆菌目分离株(挑战株77株、临床株573株)。使用FDA折点时联合组必要一致性95.7%、分类一致性98.0%、极重大误差0%;使用EUCAST折点时极重大误差为20.7%(6/21),与缺乏中介折点有关。结论为ETEST AZA在使用FDA或EUCAST标准判读时,对多种肠杆菌目提供准确、可重复的药敏结果并符合监管要求。

要点

  • FDA折点下联合组EA 95.7%、CA 98.0%、VME 0%、ME 0.2%。
  • EUCAST折点下联合组VME 20.7%(6/21),与缺乏中介折点有关。
  • 10株在标尺范围内菌株重现性100%(270/270)在模态MIC±1个倍比稀释内。

核心结论

  • ETEST AZA在使用FDA或EUCAST折点判读时,对多种肠杆菌目提供准确、可重复的药敏结果并符合监管要求。

研究设计与样本

  • 多中心研究,四个研究中心,评估ETEST AZA梯度扩散法对比参考肉汤微量稀释法,共检测650株肠杆菌目分离株(挑战株77株、临床株573株)。

主要发现

  • FDA折点下挑战株EA 97.3%(72/74)、CA 93.2%(69/74)、VME 0%、ME 0%、mE 6.8%(5/74)。
  • FDA折点下临床株EA 95.5%(504/528)、CA 98.7%(521/528)、VME 0%、ME 0.2%(1/516)、mE 1.1%(6/528)。
  • FDA折点下联合组EA 95.7%(576/602)、CA 98.0%(590/602)、VME 0%、ME 0.2%(1/577)、mE 1.8%(11/602)。
  • EUCAST折点下挑战株EA 96.1%(74/77)、CA 93.5%(72/77)、VME 31.3%(5/16);临床株EA 94.1%(539/573)、CA 99.7%(571/573)、VME 7.7%(1/13)、ME 0.2%(1/560)。
  • EUCAST折点下联合组EA 94.3%(613/650)、CA 98.9%(643/650)、ME 0.2%(1/573)、VME 20.7%(6/21),因缺乏中介折点。

关键数值与推荐

  • FDA折点下联合组EA需≥95.7%(576/602)、CA 98.0%(590/602)、VME 0%、ME 0.2%(1/577)。
  • EUCAST折点下联合组EA 94.3%(613/650)、CA 98.9%(643/650)、VME 20.7%(6/21)、ME 0.2%(1/573)。
  • 重现性测试10株在标尺范围内菌株,100%(270/270)结果在模态MIC±1个倍比稀释内。

临床怎么用

  • 临床微生物实验室可采用ETEST AZA梯度扩散法进行肠杆菌目对氨曲南-阿维巴坦的药敏试验,按FDA或EUCAST折点判读。
  • 使用EUCAST折点判读时需注意缺乏中介折点可能导致极重大误差升高。

局限性

  • EUCAST折点下因缺乏中介折点,联合组VME达20.7%(6/21),该局限性在欧洲说明书中有提及。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Aztreonam-avibactam (AZA) is a new monobactam/beta-lactamase inhibitor combination that recently received regulatory approval in the United States (U.S.) and Europe. In this study, we evaluated the performance of ETEST AZA, a gradient diffusion method, compared to reference broth microdilution for 650 challenge (n = 77) and clinical (n = 573) Enterobacterales isolates across four study sites. Using the U.S. Food and Drug Administration (FDA) interpretive breakpoints for ETEST AZA, challenge isolates demonstrated a 97.3% (72/74) essential agreement (EA), 93.2% (69/74) categorical agreement (CA), 0% very major errors (VME) and major errors (ME), and 6.8% (5/74) minor errors (mE). Clinical isolates demonstrated a 95.5% (504/528) EA, 98.7% (521/528) CA, 0% VME, 0.2% (1/516) ME, and 1.1% (6/528) mE. Overall, the combined set achieved a 95.7% (576/602) EA and 98.0% (590/602) CA, with 0% VME, 0.2% (1/577) ME, and 1.8% (11/602) mE. Using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive breakpoints, challenge isolates demonstrated a 96.1% (74/77) EA, 93.5% (72/77) CA, and 31.3% (5/16) VMEs, while clinical isolates demonstrated a 94.1% (539/573) EA and 99.7% (571/573) CA including 7.7% (1/13) VME and 0.2% (1/560) ME. The combined set demonstrated a 94.3% (613/650) EA, 98.9% (643/650) CA, 0.2% (1/573) MEs, but 20.7% (6/21) VMEs due to the lack of an intermediate breakpoint that is addressed as a limitation in the European package insert. Both bias and trending were in alignment with regulatory requirements. In reproducibility testing of 10 on-scale strains, 100% (270/270) of the results were within ±1 doubling dilution of the modal minimal inhibitory concentration. In conclusion, ETEST AZA provides accurate, reproducible susceptibility results that meet regulatory requirements for many Enterobacterales species when interpreted using FDA or EUCAST criteria. IMPORTANCE: Aztreonam-avibactam (AZA) is a novel monobactam/β-lactamase inhibitor combination approved for clinical use in the United States and Europe in 2025 and 2024, respectively. It is indicated for the treatment of multidrug-resistant Gram-negative bacteria that produce multiple classes of β-lactamases. Until recently, antimicrobial susceptibility testing for this combined agent relied on broth disk elution or microdilution using ceftazidime-avibactam and aztreonam combined. In this study, we evaluated the performance of the bioMérieux ETEST AZA gradient diffusion strip as a more streamlined method for clinical microbiology laboratories. Testing of 650 Enterobacterales isolates demonstrated that ETEST AZA met regulatory performance criteria using interpretive breakpoints from both the FDA and the European Committee on Antimicrobial Susceptibility Testing. Overall, our findings indicate that the ETEST AZA demonstrates acceptable performance for many Enterobacterales isolates and represents a practical alternative for implementing AZA susceptibility testing in clinical microbiology laboratories.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Bui TI, Csiki-Fejer E, Prudhomme S, et al. A multicenter performance evaluation of aztreonam-avibactam gradient diffusion susceptibility testing for Enterobacterales. J Clin Microbiol. 2026. PMID: 42007819. doi:10.1128/jcm.01749-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。